{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:46:10Z","timestamp":1782395170216,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001870","name":"Fundacja na rzecz Nauki Polskiej","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clgc.2026.102514","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:39:52Z","timestamp":1770856792000},"page":"102514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non\u2013Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2205-4093","authenticated-orcid":false,"given":"Piotr","family":"Doma\u0144ski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Hanusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Zapa\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paras","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Zapa\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-0191","authenticated-orcid":false,"given":"Aleksander","family":"\u015alusarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clgc.2026.102514_bib0001","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102514_bib0002","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.euo.2024.06.005","article-title":"The role of mitomycin c in intermediate-risk non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"7","author":"Scilipoti","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102514_bib0003","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and carcinoma in situ)-a summary of the 2024 Guidelines Update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102514_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091684","article-title":"Assessing the predictive accuracy of EORTC, CUETO and EAU risk stratification models for high-grade recurrence and progression after Bacillus Calmette-Gu\u00e9rin therapy in non-muscle-invasive bladder cancer","volume":"16","author":"\u015alusarczyk","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clgc.2026.102514_bib0005","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11255-019-02183-5","article-title":"Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics","volume":"51","author":"\u015alusarczyk","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clgc.2026.102514_bib0006","article-title":"Long-term quality of life in patients with bladder cancer following radical cystectomy","author":"Akdemir","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102514_bib0007","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euros.2022.12.016","article-title":"Patient preferences for treatment of Bacillus Calmette-Gu\u00e9rin-unresponsive Non-muscle-invasive bladder cancer: a cross-country choice experiment","volume":"49","author":"Collacott","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2026.102514_bib0008","article-title":"Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer","author":"Scilipoti","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102514_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00194-23","article-title":"Review of BCG immunotherapy for bladder cancer","author":"Liatsos","year":"2025","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.clgc.2026.102514_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102514_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/BLC-190245","article-title":"Salvage hyperthermic gemcitabine and docetaxel combination chemotherapy after BCG failure in non-muscle invasive bladder cancer patients","volume":"6","author":"Rao","year":"2019","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102514_bib0012","doi-asserted-by":"crossref","first-page":"40.e17","DOI":"10.1016\/j.urolonc.2019.07.022","article-title":"An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102514_bib0013","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102514_bib0014","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102514_bib0015","article-title":"Trends in treatment patterns and outcomes among patients diagnosed with nonmuscle-invasive bladder cancer in the United States","author":"Davies-Teye","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2026.102514_bib0016","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eururo.2024.08.001","article-title":"Bladder-sparing therapy for Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection","volume":"86","author":"Li","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102514_bib0017","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.clgc.2026.102514_bib0018","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102514_bib0019","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"12","key":"10.1016\/j.clgc.2026.102514_bib0020","doi-asserted-by":"crossref","first-page":"485.e1","DOI":"10.1016\/j.urolonc.2023.06.017","article-title":"Sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve and previously treated intermediate-risk nonmuscle invasive bladder cancer","volume":"41","author":"McElree","year":"2023","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102514_bib0021","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2021.03.024","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","volume":"40","author":"Steinberg","year":"2022","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102514_bib0022","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Gu\u00e9rin-Na\u00efve High-Risk Nonmuscle-Invasive Bladder Cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102514_bib0023","article-title":"Multi-institution evaluation of sequential intravesical gemcitabine and docetaxel in the treatment of Bacillus Calmette-Guerin Na\u00efve patients with non-muscle invasive bladder cancer","author":"Thomas","year":"2000","journal-title":"Clin Genitourinary Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102514_bib0024","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00345-024-04992-5","article-title":"Induction and maintenance of sequential intravesical gemcitabine\/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols","volume":"42","author":"Ben-David","year":"2024","journal-title":"World J Urol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102514_bib0025","article-title":"Intravesical Gemcitabine and Docetaxel Therapy for BCG-Na\u00efve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer","volume":"14","author":"Bakula","year":"2024","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.clgc.2026.102514_bib0026","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of Bacillus Calmette-Gu\u00e9rin\u2012Na\u00efve nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102514_bib0027","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to Bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non-muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102514_bib0028","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102514_bib0029","first-page":"33","article-title":"Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC","volume":"18","author":"Garneau","year":"2024","journal-title":"Can Urol Assoc J"},{"issue":"11","key":"10.1016\/j.clgc.2026.102514_bib0030","doi-asserted-by":"crossref","first-page":"458.e1","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102514_bib0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.urology.2024.06.020","article-title":"Sequential intravesical chemotherapy for treatment na\u00efve, high-risk non-muscle invasive bladder cancer: oncologic outcomes, tolerance, and comparison to contemporary controls","volume":"192","author":"Refugia","year":"2024","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.clgc.2026.102514_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus calmette-gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102514_bib0033","article-title":"Comparative effectiveness of Bacillus Calmette-Gu\u00e9rin and sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve intermediate-risk non-muscle-invasive bladder cancer","author":"Kolanukuduru","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102514_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.05.006","article-title":"The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer","author":"Abou Chakra","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102514_bib0035","article-title":"Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Gu\u00e9rin in patients with Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","author":"Taylor","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102514_bib0036","article-title":"Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results","author":"Scilipoti","year":"2025","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.clgc.2026.102514_bib0037","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and Update for ECOG-ACRIN EA8212: a randomized phase 3 Trial of Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-na\u00efve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.clgc.2026.102514_bib0038","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102514_bib0039","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1158\/1078-0432.CCR-24-2812","article-title":"FDA approval summary: nadofaragene firadenovec-VNCG for Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"31","author":"Colbert","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.clgc.2026.102514_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cells12121611","article-title":"Exploiting an interleukin-15 heterodimeric agonist (N803) for effective immunotherapy of solid malignancies","volume":"12","author":"Lui","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.clgc.2026.102514_bib0041","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102514_bib0042","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102514_bib0043","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non\u2013muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"issue":"33","key":"10.1016\/j.clgc.2026.102514_bib0044","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102514_bib0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with Bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102514_bib0046","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non\u2013muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102514_bib0047","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/JU.0000000000002678","article-title":"All high-grade ta tumors should be classified as high risk: bacillus calmette-gu\u00e9rin response in high-grade ta tumors","volume":"208","author":"Bree","year":"2022","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102514_bib0048","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","article-title":"Cancer-specific survival of patients with non-muscle-invasive bladder cancer: a population-based analysis","volume":"30","author":"\u015alusarczyk","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102514_bib0049","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1159\/000524098","article-title":"Quality of life, efficacy, and safety of sequential intravesical gemcitabine + docetaxel versus BCG for non-muscle invasive urinary bladder cancer: a pilot study","volume":"106","author":"Pareek","year":"2022","journal-title":"Urol Int"},{"issue":"12","key":"10.1016\/j.clgc.2026.102514_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122574","article-title":"Drug resistance driven by cancer stem cells and their niche","volume":"18","author":"Prieto-Vila","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.clgc.2026.102514_bib0051","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:44:22Z","timestamp":1774039462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1558767326000145"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102514","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non\u2013Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102514"}}